33 results about "Memory disorder" patented technology

Methods are provided for determining a memory impairment probability. The method comprises receiving one or more audio recordings of an interaction by a user with a computing device during an assessment; extracting acoustic and speech timing features from the one or more audio recordings; applying a machine learning model to the acoustic and speech timing features to generate a memory impairment probability for the user; and providing a clinical decision support recommendation for a provider based on the memory impairment probability.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The subject of the invention is an application of white birch liquid for improving memory. The invention discloses an application of a betula platyphylla sap extract in preparation of a medicine or a health food, wherein the medicine or the health food is beneficial to improving memory disorder. The invention further discloses a preparation method of the betula platyphylla sap extract, and an application of the betula platyphylla sap extract in preparation of the medicine or the health food. The white birch extract related product disclosed by the invention has the characteristics of high efficiency, safety and convenience, and can be used for effectively treating, preventing or slowing down the dysmnesia in manners of medicines, diet intervention or nutritional health-care products and the like. The invention also provides methods of treating, preventing or slowing memory disorders using the betula platyphylla extract.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

The present invention relates to a salidroside derivative, specifically a hydroxy-α-salidroside compound. The hydroxy-α-salidroside compound is superior to α-salidroside in scavenging DPPH free radicals, whitening skin, and improving learning and memory disorders. The compound can be added as a new functional ingredient to cosmetics, functional foods, or pharmaceutical compositions. The preparation method of the hydroxy-α-salidroside of the present invention uses α-salidroside as a substrate and synthesizes hydroxy-α-salidroside under the action of hydroxylase.

The invention provides an electroencephalogram signal-based dysmnesia assessment system, which comprises a signal acquisition module for acquiring an electroencephalogram signal of a target object; the preprocessing module is used for performing 0.5-40Hz band-pass filtering on the electroencephalogram signal of the target object; the signal segmentation module is used for segmenting each channel and determining a plurality of non-overlapping Epoches corresponding to each channel; the feature extraction module is used for performing linear feature extraction and nonlinear feature extraction on each Epoch in each channel, and determining electroencephalogram signal fusion features of the target object based on the linear feature and the nonlinear feature of each Epoch; and the dysmnesia assessment module is used for inputting the electroencephalogram signal fusion features into a trained dysmnesia assessment model, and performing dysmnesia assessment on the target object by using the dysmnesia assessment model to obtain a dysmnesia assessment result of the target object. According to the scheme, dysmnesia evaluation of the target object can be efficiently realized.

Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.

The invention discloses an application of mitochondrial topoisomerase I or a coding gene thereof, relates to the technical field of biological medicines, and particularly provides an application of the mitochondrial topoisomerase I or the coding gene thereof as a therapeutic target in screening or preparing a medicine for treating Alzheimer's disease. The action mechanism of the mitochondrial topoisomerase I in the Alzheimer's disease is fully explored, it is found that deletion of the coding gene of the mitochondrial topoisomerase I can cause increase of APP and A beta levels and finally cause learning and memory impairment similar to the Alzheimer's disease, and the mitochondrial topoisomerase I can be used as a potential target for treatment of the Alzheimer's disease and can be used for treating the Alzheimer's disease. The overexpressed mitochondrial topoisomerase I can significantly reduce APP and A beta levels and treat the Alzheimer's disease.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

1. Name of the Design Product: Dynamic Graphical User Interface for Neurorehabilitation Training of Display Screen Panel. 2. Use of the Design Product: Used for displaying graphical user interface and interaction. 3. Design Key Points of the Design Product: Lie in the interface content of the graphical user interface on the screen. 4. Picture or Photo that Best Illustrates the Design Key Points: Front View. 5. The display screen panel is of conventional design, so the left view, right view, top view, bottom view are omitted; the rear view is omitted. 6. Use of the Graphical User Interface: Used for the rehabilitation training of patients with memory disorders. 7. Human-Machine Interaction Method of the Graphical User Interface: Clicking, voice prompts, and blood oxygen data of the trainee. 8. Explanation of the Changing States of the Graphical User Interface: The front view is the welcome interface for neurorehabilitation training, with a voice prompt "Training items are being loaded, please wait a moment" and enters the interface changing state diagram 1, which is the training item loading interface; the interface changing state diagram 2 is the interface when the item loading is about to be completed; the interface changing state diagram 3 is the resting state interface during the training process of the trainee after the loading of the item is completed; the interface changing state diagram 4 is the interface ending the resting state stage, and a voice prompt: "Please try to remember the colored graphics that appear on the carriage" is given, and at the same time as the voice prompt, it enters the interface changing state diagram 5; the interface changing state diagram 5 is the teaching training stage interface during the training process of the trainee, the interface changing state diagram 6 is the animation interface at the end of the teaching training stage of the trainee; the interface changing state diagram 7 is the animation interface at the end of the teaching training stage of the trainee; from the interface changing state diagram 3 to the interface changing state diagram 4 is the resting state stage during the training process; from the interface changing state diagram 5 to the interface changing state diagram 7 is the teaching training stage during the training process, and while testing from the interface changing state diagram 3 to the interface changing state diagram 7, the blood oxygen concentration of the trainee is determined and then enters the interface changing state diagram 8, which is the interface showing the start screen of the training; the interface changing state diagrams 9-13 are the interfaces of the training questions; in the interface changing state diagrams 9 to 13, the vines on the roof of the carriage become longer or shorter according to the blood oxygen concentration of the trainee; the interface changing state diagram 13 is the last question, and after the end, it enters the interface changing state diagram 14, and at the same time a voice prompt: "Training ended". 9. Other Situations Requiring Explanation: Other Explanation: The display screen panel and the displayed graphical user interface are applied to computers, laptops, tablets, and mobile phones. The blood oxygen concentration data is received through a communication connection in the near-infrared data acquisition module.

The invention discloses a proteolysis targeting chimeric molecule capable of degrading PTBP1 in a targeting manner as well as a preparation method and application of the proteolysis targeting chimeric molecule. The invention relates to a protease targeted chimeric RNA-PTAC of a nucleic acid ligand. The protease targeted chimeric RNA-PTAC is formed by connecting an E3 ubiquitin ligase ligand pomalidomide and an RNA fragment capable of being specifically combined with PTBP1 protein through polyethylene glycol Linker. The invention relates to an RNA-PROTAC (Ribonucleic Acid-PROTAC) brain targeting delivery preparation, which is a complex obtained by coupling cell penetrating peptides TAT and RVG (Recombinant Virus Growth) with the RNA-PROTAC. According to the TR + RNA-PROTAC complex disclosed by the invention, the targets of efficiently degrading PTBP1 protein in vitro and degrading PTBP1 protein in a brain in a targeted manner in vivo are achieved through the complex, and in-vivo experiments also prove that the TR + RNA-PROTAC complex can be used for treating learning and memory disorders of mice caused by A beta and shows a good curative effect of resisting Alzheimer's disease.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.

The present invention provides a method of treating Parkinson's disease by light stimulation in which light of a specific wavelength such as violet light is irradiated at a specific blinking frequency. The present invention, by irradiating light of a specific wavelength such as violet light to a living body, carries out treatment and / or prophylaxis of Parkinson's disease by improving or suppressing at least one symptom selected from a group of symptoms consisting of cognitive memory disorder, working memory disorder, dysphoria, anxiety, apathy, psychological symptoms (hallucination, visual hallucination, and auditory hallucination), impulse control disorder, orthostatic hypotension, urinary disorder, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorder, pain, weight loss, olfactory abnormality, fatigue, and diaphoresis.

The present invention provides a novel memory disorder ameliorating agent. A PKC [gamma] activity inhibitor is useful as an active ingredient of a dysmnesia ameliorating agent.

The invention discloses an application of HOPX in improving / treating hippocampal dependent dysmnesia. According to the present invention, the rejuvenation or the function up-regulation of the HOPX is directly associated with the aging reversal-related hippocampus memory decline for the first time, and the brand new path and the strategy for treating the age-related cognitive impairment are opened up; in-vivo experiments prove that retrophication / overexpression of HOPX can directly resist hippocampal neurogenesis reduction caused by aging and improve phenotypes from cell and molecule levels. The invention provides a solid theoretical and experimental basis for developing HOPX-based gene therapy, protein drugs or small molecule agonists, and has a good transformation application prospect.

The present invention relates to: a composition for improving cognitive function, comprising a natural extract complex; and use thereof. According to an embodiment of the present invention, a composition for improving cognitive function or memory, comprising one or more selected from the group consisting of a Perilla frutescens var. acuta kudo extract, a Moringa oleifera extract, and a Phyllanthus emblica extract, exhibits few side effects due to being based on natural substances, is readily available, and provides an excellent cognitive function improvement effect while being cost-effective. Therefore, the composition can be effectively used for the prevention, amelioration or treatment of diseases associated with cognitive or memory impairment.

The invention provides a brain disease classification prediction method based on brain-like calculation, aims at solving the problem that a brain network cannot be effectively combined with a brain-like calculation method, and is effectively applied to diagnosis and classification of brain diseases. On one hand, the high-order multi-mode brain network constructed by the method integrates brain structure and function information and structure-function coupling information, information loss caused by independent analysis of a structure network and a function network is overcome, multi-scale understanding of a brain mechanism and an abnormal mode is realized, and extraction of pathological features of people with brain diseases is facilitated. In addition, the brain disease classification prediction application model based on the brain-like calculation method provided by the invention combines the characteristics of GCN and SNN, obtains relatively high accuracy in classification prediction of cognitive memory impairment diseases, shows the potential of brain-like calculation in the field of brain science application, and provides a new technical means for diagnosis and intervention of brain diseases.

A construction method for an experimental animal learning and memory impairment model, comprising: individually housing a CD-1 mouse to allow the CD-1 mouse to develop territorial awareness; subjecting an experimental mouse and the CD-1 mouse to physical confrontation in a cage for a preset duration; and once the experimental mouse has developed acute violent stress, placing the experimental mouse into a Skinner box apparatus to perform a learning ability test, after a preset duration, performing a memory ability test, and after the tests, obtaining the experimental animal learning and memory impairment model. The method assesses animal learning and memory abilities by means of a Skinner box, expands assessment means related to learning and memory, and provides new data support for the construction and assessment of an animal model involving learning and memory impairment induced by acute violent stress.

This application pertains to a compound of Formula (I), Formula (I'), Formula (I") or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X, R1, R2, R3, R5, R6, and R7 are as defined herein, and uses of such compounds in methods of treating neurodegenerative diseases, neurodevelopmental disorders, and age-related memory impairment.

The invention discloses a construction method and application of a model for senescence with cognitive impairment and hypomnesia, and belongs to the technical field of medicine, health food and food efficacy evaluation. According to the senescence accompanied cognitive disorder and hypomnesia model construction method, zebra fish D-galactose is combined with physical stimulation induction to successfully establish the senescence accompanied cognitive disorder and hypomnesia model, phenomenon observation is visual, senescence accompanied cognitive disorder and hypomnesia definition is accurate, and the method is suitable for popularization and application. The method can effectively and rapidly evaluate the effects of medicines, health-care foods and foods in improving senescence accompanied by cognitive impairment and hypomnesia, and provides an effective and rapid detection approach for medicines, health-care foods and foods in improving senescence accompanied by cognitive impairment and hypomnesia.

The application provides a memory disorder evaluation system based on an electroencephalogram, comprising: a signal acquisition module configured to acquire an electroencephalogram of a target object; a preprocessing module configured to perform a band-pass filtering of 0.5Hz-40Hz on the electroencephalogram of the target object; a signal segmentation module configured to segment each channel and determine a plurality of non-overlapping Epochs corresponding to each channel; a feature extraction module configured to perform linear feature extraction and nonlinear feature extraction on each Epoch in each channel, and determine an electroencephalogram fusion feature of the target object based on the linear feature and the nonlinear feature of each Epoch; and a memory disorder evaluation module configured to input the electroencephalogram fusion feature into a trained memory disorder evaluation model, use the memory disorder evaluation model to evaluate the memory disorder of the target object, and obtain a memory disorder evaluation result of the target object. The scheme can efficiently evaluate the memory disorder of the target object.

The present invention discloses a pharmaceutical composition for preventing and treating AD, comprising 50 to 100 parts by weight of salidroside, 60 to 80 parts by weight of protocatechuic acid, 70 to 80 parts by weight of wedelol, 50 to 80 parts by weight of apigenin, 30 to 60 parts by weight of luteolin and 10 to 30 parts by weight of oleanolic acid. The present invention also discloses the use of a pharmaceutical composition for preventing and treating AD as a central nervous system protective agent. The present invention illustrates through behavioral, morphological and immunological experiments that intraperitoneal injection of D-gal can successfully replicate a mouse learning and memory disorder model, and that both the pharmaceutical composition and the positive drug can improve the mouse's ability to explore new things, working memory ability and spatial exploration ability, improve the structural morphology of hippocampal neurons, increase the number of hippocampal neurons and the number of Nissl bodies, thereby exerting a neuroprotective effect on D-gal model mice, providing an experimental and theoretical basis for the clinical application of the pharmaceutical composition in preventing and treating AD and the development of new anti-AD traditional Chinese medicines.

The invention relates to the technical field of medical preparations, in particular to a medicine for improving sleep deprivation induced dysmnesia or depressive symptoms. It is found that the cannabinoid composition composed of cannabidiol and cannabinocene can significantly improve sleep deprivation induced dysmnesia and depression-like changes through a synergistic effect, significantly reduce microglial cell M1 subtype markers, reduce polarization of pro-inflammatory subtypes and increase polarization of anti-inflammatory M2 subtypes. According to the application, the increase of sleep deprivation induced proinflammatory cytokines can be reduced, the concentration of anti-inflammatory cytokines can be improved, and a scientific basis is provided for treating sleep deprivation induced dysmnesia and depression-like change by cannabinoid.

The present disclosure relates to a composition for preventing or treating brain-related inflammation disease or neurodegenerative disease, comprising entrectinib. The composition exhibits an effect of inhibiting brain-related inflammation and alleviating memory impairment, and thus may be usefully used for the prevention, alleviation, or treatment of brain-related inflammation disease, neurodegenerative disease, memory impairment, etc.

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

The application belongs to an animal model, and aims to solve the technical problems that the evaluation method of the current Skinner box experimental data lacks a systematic experimental paradigm and evaluation means, and lacks related parameters, and provides an experimental animal learning and memory disorder model, a construction method and application. The traditional chronic social frustration model experiment process is optimized, the learning and memory disorder model of the mouse is stably induced, and the obtained experimental animal learning and memory disorder phenotype is obvious, and the diversity of stress-related disorder animal models is enriched. The learning and memory ability of the animal is evaluated by the Skinner box, the learning and memory related evaluation means is expanded, and new data support is provided for the construction and evaluation of the acute violent stress induced learning and memory disorder animal model.

To provide a method for evaluating dementia, and a composition for preventing or treating a decline in brain function, or for maintaining or improving brain function. [Solution] The gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease were compared. As a result, microorganisms belonging to the genus Faecalibacterium were selected as gut microbiota associated with cognitive function. Furthermore, it was revealed that Faecalibacterium prausnitzii, which possesses specific DNA, has an improving effect on cognitive decline such as learning and memory impairment.

The invention belongs to the technical field of essential oil, and particularly provides compound essential oil for improving learning and memory disorders as well as a preparation method and application of the compound essential oil. The liquid compound essential oil comprises the following raw materials in parts by weight: 30-40 parts of ginseng essential oil, 10-15 parts of rhizoma acori graminei essential oil, 1-5 parts of frankincense essential oil, 30-40 parts of perilla essential oil, 1-5 parts of borneol and 1-5 parts of ginkgo leaf essential oil. The compound essential oil for improving learning and memory disorders provided by the invention takes multiple traditional Chinese medicine extracts as raw materials, so that the compound essential oil has the effects of tonifying qi and inducing resuscitation, refreshing mind and restoring consciousness, soothing nerves and stabilizing mind and enhancing memory.